The Guardian view on peptides: Robert F Kennedy Jr would leave public health policy to the hucksters | Editorial
Why it matters: RFK Jr.'s plan would allow public sale of 14 unproven peptide drugs, reversing FDA restrictions and potentially exposing individuals to significant safety risks.
- Robert F. Kennedy Jr. plans to open the sale of "about 14" injectable peptide drugs to the public, aligning with his Maha agenda's emphasis on personal choice and deregulation.
- The US Food and Drug Administration (FDA) restricted 17 peptides in 2023 due to "potential significant safety risks," noting none have been proven safe or effective for human use.
- Peptides, while some show promise in treating disease, are widely promoted for biological enhancement (e.g., muscle mass, cognitive benefits) with thin human evidence, leading to widespread self-administration from grey markets, particularly in Silicon Valley.
- The Maha project aims to transform the grey market for unproven substances into the primary market by removing proscriptions rather than seeking full FDA endorsement, effectively sanctioning mass public use.
Robert F. Kennedy Jr.'s "Make America Healthy Again" (Maha) agenda, which prioritizes personal choice over public health interventions, is poised to open the sale of approximately 14 injectable peptide drugs to the public, despite the FDA restricting 17 similar peptides in 2023 due to "potential significant safety risks" and a lack of proven safety or efficacy. This move, which sidelines scientific expertise for "wellness" hucksters, would effectively sanction mass public use of unproven substances, a practice already prevalent in grey markets and among those seeking biological enhancement.
